Vanguard Global Advisers »

Lineage Cell Therapeutics In shares owned by Vanguard Global Advisers

Quarter-by-quarter ownership of Lineage Cell Therapeutics In (LCTX) shares owned by Vanguard Global Advisers from 13F filings

Historical chart of Vanguard Global Advisers investment in Lineage Cell Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including Lineage Cell Therapeutics In held by Vanguard Global Advisers consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lineage Cell Therapeutics In by Vanguard Global Advisers

Quarter filed Position value Share count Share price at filing
2026-03-31 $136k 86k 1.58

More positions owned by Vanguard Global Advisers

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Vanguard Index Fds Total Stk Mkt (VTI)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Broadcom (AVGO)
Alphabet Cap Stk Cl C (GOOG)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Meta Platforms Cl A (META)
Tesla Motors (TSLA)
Vanguard Specialized Funds Div App Etf (VIG)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
JPMorgan Chase & Co. (JPM)

View all positions for Vanguard Global Advisers

Top funds holding Lineage Cell Therapeutics In

Broadwood Capital
Vanguard Group
Vanguard Capital Management
Defender Capital
Millennium Management
Raffles Associates
Fifth Third Bancorp
Brian McDonald
BlackRock
Armistice Capital
Geode Capital Management
Renaissance Technologies
Morgan Stanley
UBS Group
Marshall Wace

View all funds holding Lineage Cell Therapeutics In